Halobetasol
Corticosteroids, Potent (Group Iii)
- Drug class
- Corticosteroids, Potent (Group Iii)
- Availability
- Prescription only
- Routes
- Topical
- Markets covered
- 1
- Products on record
- 1
Overview
Halobetasol is an active pharmaceutical ingredient in the Corticosteroids, Potent (Group Iii) group (D07AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | May 29, 2024 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Use in children under 12 years of age is not recommended. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
How to take
Sources & citations
- [1]FDA DailyMed · 14766ad1-d61d-48… · revised May 29, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.